ACOG Alpha Cognition: Forward P/S Multiple
Alpha Cognition develops innovative treatments for Alzheimer's, targeting the global neurology sector. A complex certification process and patents protect its developments from replication, while critical demand enables the company to maintain pricing power. This forward price-to-sales valuation chart from GURU.Markets visualizes the volatility of market expectations, where 9.30 serves as the final level marker.
Analytical breakdowns for alphacognition.com (ACOG)
- market price and analyst price targets:
- company stock capitalization data:
- issuer book value statistics:
- debt and liquidity details:
Total Debt to Equity Ratio Alpha Cognition|ACOG - Long-Term Loans to Capital Ratio|Short-Term Debt to Capital Alpha Cognition Inc.|ACOG - Company Total Debt Obligations|Debt to Book Capitalization Ratio Alpha Cognition Inc.|ACOG - Long-Term Debt|Company Short-Term Debt Alpha Cognition|Quick Ratio alphacognition.com
- business earnings and investment ratios data:
ACOG - Net Profit|Projected Future Earnings Alpha Cognition|ACOG - Price to Earnings Ratio|Future Price to Earnings Alpha Cognition Inc.|ACOG - Price to Earnings Adjusted for Growth Rate|EV/EBITDA Multiple Alpha Cognition Inc.|ACOG - Operating profit before depreciation charges|Earnings per share for the last twelve months Alpha Cognition|ACOG - Earnings per share for the last 12 months|Quarterly EPS earnings growth alphacognition.com|ACOG - Earnings per share growth rate in current year|Expected earnings per share growth for next year Alpha Cognition
- sales and revenue indicators:
Comprehensive company analysis:ACOG (Alpha Cognition Corp)
For Alpha Cognition (ACOG), which possesses significant pricing power due to the unique delivery method of the drug Zunveyl, this indicator reflects the ratio of current market capitalization to expected future sales volume. Analyzing the forward revenue multiple allows investors to efficiently assess business value between quarterly reports, mitigating the risk of missing the entry point and protecting capital from sharp drawdowns amid inelastic demand.
Competitor analysis
Price-to-Projected Revenue Ratio Biogen BIIB|Neurocrine (NBIX) - Market Cap to Future Revenue Ratio|Regencell - Forward P/S Multiple|Projected Price to Revenue Axsome Corp (AXSM)|ACADIA Pharmaceuticals (ACAD) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue XENE|VKTX (Viking Therapeutics, Inc.) - Forward P/S Multiple|Supernus Pharmaceuticals, Inc. (SUPN) - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple CPRX (Catalyst Pharmaceuticals Inc)|Price to Expected Revenue Ratio DNLI|Forward P/S Multiple HRMY (Harmony Biosciences)|Market Cap to Expected Sales Ratio biohavenpharma.com (BHVN)|AMLX - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Trevi Therapeutics Inc|Praxis Medicines (PRAX) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue AVXL|CBLL (CeriBell, Inc.) - Forward P/S Multiple|Forward P/S Multiple Prothena Corporation|Forward P/S Multiple ALEC|Forward Price-to-Revenue Multiple Annexon Biosciences ANNX|Price-to-Projected Revenue Ratio Omeros OMER|Neurogene Therapeutics (NGNE) - Market Cap to Future Revenue Ratio|AC Immune - Forward P/S Multiple|Projected Price to Revenue voyagertherapeutics.com (VYGR)|Neumora Therapeutics, Inc. (NMRA) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue SCLX|TVGN (Tevogen Bio Holdings, Inc.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Cognition Therapeutics Inc. CGTX|Forward Price-to-Revenue Multiple IKT (Inhibikase Therapeutics)|Forward P/S Multiple cassavasciences.com (SAVA)|Price-to-Projected Revenue Ratio Assertio ASRT|Forward Price to Sales COYA|VTGN - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Ovid Therapeutics Inc.|ABOS: Forward P/S Multiple|cervomed.com (CRVO) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Alterity Therapeutics Ltd.|Price-to-Projected Revenue Ratio CLNN|Price-to-Projected Revenue Ratio PepGen Inc. (PEPG)|JUNS: Future Price to Revenue|Forward P/S Multiple RLMD (Relmada Therapeutics)|Forward Price to Sales ANVS|Grace Tx - Forward P/S Multiple|AIFF - Forward P/S Multiple|KLTO (anewmeds.com) - Forward Price-to-Revenue Multiple|NeuroSense Therapeutics Ltd. - Forward Price to Sales|RVPH (Reviva Pharmaceuticals) - Forward P/S Multiple|Forward Price-to-Revenue Multiple MetaVia, Inc. (MTVA)|Price-to-Projected Revenue Ratio NeurAxis (NRXS)|HSDT - Market Cap to Future Revenue Ratio|Forward P/S Multiple PASG (Passage Bio)|Projected Price to Revenue Neuphoria Therapeutics, Inc.|NERV - Price-to-Projected Revenue Ratio|ATHA (athira.com) - Market Cap to Projected Revenue|ADXN: Forward P/S Multiple|ALZN - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple CYCN|PTIX (Protagenic) - Price to Expected Revenue Ratio|Forward P/S Multiple KTTA|Market Cap to Expected Sales Ratio cortigent.com|Price-to-Projected Revenue Ratio Avenue Therapeutics, Inc. ATXI|Brainstorm Cell Therapeutics Inc. (BCLI) - Market Cap to Future Revenue Ratio|CARA - Price-to-Projected Revenue Ratio|CHRO (Chromocell) - Market Cap to Projected Revenue|ELYM: Forward P/S Multiple|Intra-Cellular Therapies, Inc. (ITCI) - Forward P/S Multiple|LBPH (Longboard Pharmaceuticals, Inc.) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Marinus Pharmaceuticals Inc (MRNS)|Price-to-Projected Revenue Ratio NKGen (NKGN)|NRBO - Market Cap to Future Revenue Ratio|Forward P/S Multiple SAGE (Sage Therapeutics, Inc.)|Projected Price to Revenue synaptogen.com|TRVN - Price-to-Projected Revenue Ratio|VIGL (Vigil Neuroscience) - Market Cap to Projected Revenue|WENA: Forward P/S Multiple|Market Cap to Future Revenue Ratio Cerevel Corp (CERE)
